We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Next-generation RNA vaccines
- Dr. Anna Blakney
-
34. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
35. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
36. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
37. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
38. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
39. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
40. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
41. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
42. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
43. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
44. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
45. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
47. HCV resistance
- Prof. John Dillon
-
48. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
49. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
50. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
51. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
52. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
53. Cow’s milk allergy: the future
- Dr. Carina Venter
-
54. Cow's milk allergy: management
- Dr. Carina Venter
-
55. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
56. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
57. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
58. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
59. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
60. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
61. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
62. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
63. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
64. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
66. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
67. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
68. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
70. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
71. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
72. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
73. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
74. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
75. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
76. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
77. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
78. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
79. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
80. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
81. Peptide-drug conjugates as therapeutic modality in drug development 1
- Dr. Syed Faheem Askari Rizvi
-
82. Peptide-drug conjugates as therapeutic modality in drug development 2
- Dr. Syed Faheem Askari Rizvi
-
83. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
84. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
85. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
86. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
87. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
88. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
89. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
90. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
91. AI and big data in drug discovery
- Mr. Ed Addison
-
92. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
93. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
94. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
95. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
96. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
97. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
98. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
99. Diagnosis of tuberculosis and drug resistant tuberculosis 1
- Dr. Daniela Cirillo
-
100. Diagnosis of tuberculosis and drug resistant tuberculosis 2
- Dr. Daniela Cirillo
-
101. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
102. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
103. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
104. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
105. New drugs for asthma
- Prof. Peter Barnes
-
106. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
107. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Drug-resistant tuberculosis (DR-TB)
- Updated definition of pre and extensively resistant tuberculosis
- The MDR crisis
- New MDR regimens
- Setting up the appropriate break points requires standardisation
- Definitions : WHO, CLSI, EUCAST
- Antimicrobial susceptibility testing (AMST) of mycobacteria: EUCAST
- Relevance of lineages on breakpoints
- Evaluation of CC for pretomanid and cycloserine
- Molecular tests for the diagnosis of DR-TB
- Molecular diagnostics is recommended for the detection of RR
- Should we continue using pyrazinamide (PZA) without sensitivity confirmation?
- NGS
- tNGS for rapid screening of known genes associated with resistance
- New drugs mechanisms of action
- MTB linezolid-resistance associated mutation mechanism
- The challenge of detecting bedaquiline resistance with molecular assays
- Efflux pump mediated bedaquiline resistance/hypersensitivity mechanisms
- Delamanid resistance targets and mutations
- Mechanisms leading to new DR
- tNGS
- Alternative to sputum for diagnosis and screening
- Gaps in diagnostics
- Take home message
- References
- Thank you
Topics Covered
- Drug-resistant tuberculosis
- Drug sensitivity
- Multiple drug resistant TB (MDR-TB)
- MDR crisis
- Lineage breakpoints
- Molecular tests for the diagnosis of DR-TB
- New drugs mechanisms of action
- Mechanisms leading to new DR
- Alternatives to sputum test
Links
Series:
Categories:
Therapeutic Areas:
External Links
- Slides 3-7- Global Tuberculosis Report 2023
- Slide 12-14- WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection
- Slide 12- Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance
- Slide 12- WHO launches new guidance on the use of targeted next-generation sequencing tests for the diagnosis of drug-resistant TB and a new sequencing portal
- Slide 12- Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis
- Slide 12- Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis
- Slide 15- Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance
- Slide 15- Guidance for the surveillance of drug resistance in tuberculosis
- Slide 15- The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide
- Slide 17- Clockwork
- Slide 22,31- WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection
- Slide 26- WHO consolidated guidelines on tuberculosis: module 4: treatment and care
- Slide 28- Consultation on breakpoint changes necessary in conjunction with introducing new definitions of S, I and R in the EUCAST breakpoint Table v 9.0.
- Slide 29- Antimicrobial susceptibility testing of Mycobacteria: EUCAST
- Slide 29- SOP for calibrating surrogate MIC methods for M. tuberculosis against the EUCAST reference MIC method
- Slide 30- BCCM/ITM Mycobacteria Collection
Talk Citation
Cirillo, D. (2025, July 31). Diagnosis of tuberculosis and drug resistant tuberculosis 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 30, 2025, from https://doi.org/10.69645/FGZS4274.Export Citation (RIS)
Publication History
- Published on July 31, 2025
Financial Disclosures
- There are no commercial/financial matters to disclose.
Diagnosis of tuberculosis and drug resistant tuberculosis 2
Published on July 31, 2025
32 min
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:04
Let's now focus on
drug-resistant tuberculosis.
Drug-resistant tuberculosis
is caused by a strain of
MTB complex resistant to any of
the relevant TB drugs
used in the regimen.
We have mono-resistant phases.
This is the most widespread form
of drug-resistant
tuberculosis and
the resistance to
isoniazid is very common.
Isoniazid-resistant
tuberculosis requires a change
in the therapy strategy.
It needs to be recognized
as early as possible.
We do have mono-resistant
tuberculosis to rifampicin.
In this case,
the same strategy that we
used to detect MDR is used.
Actually, the majority of the
tests that we call a test for
MDR that are
commercially available
only detect rifampicin
resistance.
We assume that being rifampicin
resistant is less common
than isoniazid resistance,
having a dose mutation
developing more rarely;
the vast majority
of strains that
become rifampicin resistant have
already accumulated
a mutation that
has made them
isoniazid resistant.
Rifampicin resistance
is a good proxy of MDR.
But we still have a consistent
number of cases that
are isoniazid-sensitive
and rifampicin-resistant.
Anyway, the bottom line is
that rifampicin
resistance and MDR
follow the same
guidelines for treatment.
We define MDR-TB as
TB strains that are resistant
to rifampicin and isoniazid.